Database Query Results : , , TET2

TET2, tet oncogene family member 2: Click to Expand ⟱
Source: CGL-Driver Genes
Type: TSG
TET2 (Ten-Eleven Translocation 2) is a gene that encodes an enzyme involved in the process of DNA demethylation, which is crucial for regulating gene expression and maintaining genomic stability.
TET2 is a critical epigenetic regulator whose dysregulation—mainly through mutations—plays a significant role in the development and progression of various cancers, particularly in hematologic malignancies. Its impact on DNA methylation and subsequent gene expression changes makes it a key player in oncogenesis and a potential target for epigenetic therapies. The prognostic implications of TET2 mutations are context-dependent, contributing valuable information regarding disease progression, patient outcomes, and treatment response.

Loss-of-function mutations or reduced activity of TET2 can lead to aberrant DNA methylation patterns, which may result in inappropriate gene silencing (including of tumor suppressor genes) or activation of oncogenes. This disruption in the normal epigenetic landscape contributes to the development and progression of various cancers, particularly hematological malignancies such as myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML).
Scientific Papers found: Click to Expand⟱
3435- aLinA,    Alpha-linolenic acid-mediated epigenetic reprogramming of cervical cancer cell lines
- in-vitro, Cerv, HeLa - in-vitro, Cerv, SiHa - in-vitro, Cerv, C33A
DNMTs↓, HDAC↓, HATs↑, hTERT/TERT↓, CDH1↑, RARβ↑, DNMT1↓, DNMT3A↓, TET2↑, HDAC1↓, HDAC8↓, SIRT1↓, HMTs↑, EZH2↓,
2915- LT,    Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells
- in-vitro, Colon, HT29 - in-vitro, CRC, SNU-407 - in-vitro, Nor, FHC
DNMTs↓, TET1↑, NRF2↑, HDAC↓, tumCV↓, BAX↑, Casp9↑, Casp3↑, Bcl-2↓, ROS↓, GSS↑, Catalase↑, HO-1↑, DNMT1↓, DNMT3A↓, TET1↑, TET3↑, TET2↓, P53↑, P21↑,
3427- TQ,    Chemopreventive and Anticancer Effects of Thymoquinone: Cellular and Molecular Targets
ROS⇅, Fas↑, DR5↑, TRAIL↑, Casp3↑, Casp8↑, Casp9↑, P53↑, mTOR↓, Bcl-2↓, BID↓, CXCR4↓, JNK↑, p38↑, MAPK↑, LC3II↑, ATG7↑, Beclin-1↑, AMPK↑, PPARγ↑, eIF2α↓, P70S6K↓, VEGF↓, ERK↓, NF-kB↓, XIAP↓, survivin↓, p65↓, DLC1↑, FOXO↑, TET2↑, CYP1B1↑, UHRF1↓, DNMT1↓, HDAC1↓, IL2↑, IL1↓, IL6↓, IL10↓, IL12↓, TNF-α↓, iNOS↓, COX2↓, 5LO↓, AP-1↓, PI3K↓, Akt↓, cMET↓, VEGFR2↓, CXCL1↓, ITGA5↓, Wnt↓, β-catenin/ZEB1↓, GSK‐3β↓, Myc↓, cycD1/CCND1↓, N-cadherin↓, Snail↓, Slug↓, Vim↓, Twist↓, Zeb1↓, MMP2↓, MMP7↓, MMP9↓, JAK2↓, STAT3↓, NOTCH↓, cycA1/CCNA1↓, CDK2↓, CDK4↓, CDK6↓, CDC2↓, CDC25↓, Mcl-1↓, E2Fs↓, p16↑, p27↑, P21↑, ChemoSen↑,
3426- TQ,    Thymoquinone-Induced Reactivation of Tumor Suppressor Genes in Cancer Cells Involves Epigenetic Mechanisms
- in-vitro, BC, MDA-MB-468 - in-vitro, AML, JK
UHRF1↓, DNMT1↓, DNMT3A↓, DNMTs↓, HDAC1↓, HDAC4↓, HDAC↓, DLC1↑, PPARγ↑, FOXO↑, TET2↑, CYP1B1↑, G9a↓,
632- VitC,    High-Dose Vitamin C: Preclinical Evidence for Tailoring Treatment in Cancer Patients
- Review, NA, NA
SVCT-2∅, ROS↑, Hif1a↓, PARP∅, TET2↑,
3118- VitC,    Vitamin C boosts DNA demethylation in TET2 germline mutation carriers
- Trial, Nor, NA
TET2↑,
3119- VitC,    Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma
- in-vitro, RCC, NA
TET2↑, TumCG↓, tumCV↓,
3120- VitC,    Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells
- in-vitro, lymphoma, NA
TET2↑, Smad1↑, ChemoSen↑, other↝,
3121- VitC,  immuno,    Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma
- in-vivo, RCC, A498 - in-vitro, RCC, 786-O
TET2↑, eff↑, eff↑,
3122- VitC,    Ascorbic Acid Promotes Plasma Cell Differentiation through Enhancing TET2/3-Mediated DNA Demethylation
TET2↑, TET3↑,
3123- VitC,    Ascorbic Acid Enhances Tet-Mediated 5-Methylcytosine Oxidation and Promotes DNA Demethylation in Mammals
- in-vitro, Nor, mESC
*TET2↑, other↝,
3124- VitC,    Ascorbic acid improves parthenogenetic embryo development through TET proteins in mice
- in-vivo, Nor, NA
TET2↑, TET1↑, TET3↑,
3114- VitC,    Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression
- in-vitro, AML, NA
TET2↑, eff↑, ROS↑, Fenton↑, Hif1a↓,
3113- VitC,    Vitamin C enhances NF-κB-driven epigenomic reprogramming and boosts the immunogenic properties of dendritic cells
- in-vitro, Nor, NA
TET2↑, NF-kB↑,
3148- VitC,    Antioxidants in brain tumors: current therapeutic significance and future prospects
- Review, Var, NA
*antiOx↑, *ROS↓, chemoPv↑, ChemoSen↑, TET2↑, eff↑, OS↑, QoL↑, eff↑,
3142- VitC,    Vitamin C promotes apoptosis in breast cancer cells by increasing TRAIL expression
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7 - in-vitro, Nor, MCF12A
TET2↑, Apoptosis↑, TRAIL↑, BAX↑, Casp↑, Cyt‑c↑, HK2↓, PDK1↓, BNIP3↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 16

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned ⓘ

chemoPv↑, 1,  

Redox & Oxidative Stress ⓘ

Catalase↑, 1,   Fenton↑, 1,   GSS↑, 1,   HO-1↑, 1,   NRF2↑, 1,   ROS↓, 1,   ROS↑, 2,   ROS⇅, 1,  

Mitochondria & Bioenergetics ⓘ

CDC2↓, 1,   CDC25↓, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   ATG7↑, 1,   HK2↓, 1,   PDK1↓, 1,   PPARγ↑, 2,   RARβ↑, 1,   SIRT1↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,   BAX↑, 2,   Bcl-2↓, 2,   BID↓, 1,   Casp↑, 1,   Casp3↑, 2,   Casp8↑, 1,   Casp9↑, 2,   Cyt‑c↑, 1,   DR5↑, 1,   Fas↑, 1,   hTERT/TERT↓, 1,   iNOS↓, 1,   JNK↑, 1,   MAPK↑, 1,   Mcl-1↓, 1,   Myc↓, 1,   p27↑, 1,   p38↑, 1,   survivin↓, 1,   TRAIL↑, 2,  

Transcription & Epigenetics ⓘ

EZH2↓, 1,   HATs↑, 1,   other↝, 2,   TET3↑, 3,   tumCV↓, 2,  

Protein Folding & ER Stress ⓘ

eIF2α↓, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   BNIP3↓, 1,   LC3II↑, 1,  

DNA Damage & Repair ⓘ

CYP1B1↑, 2,   DNMT1↓, 4,   DNMT3A↓, 3,   DNMTs↓, 3,   G9a↓, 1,   p16↑, 1,   P53↑, 2,   PARP∅, 1,   UHRF1↓, 2,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 1,   cycA1/CCNA1↓, 1,   cycD1/CCND1↓, 1,   E2Fs↓, 1,   P21↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

cMET↓, 1,   ERK↓, 1,   FOXO↑, 2,   GSK‐3β↓, 1,   HDAC↓, 3,   HDAC1↓, 3,   HDAC4↓, 1,   HDAC8↓, 1,   HMTs↑, 1,   mTOR↓, 1,   NOTCH↓, 1,   P70S6K↓, 1,   PI3K↓, 1,   STAT3↓, 1,   TumCG↓, 1,   Wnt↓, 1,  

Migration ⓘ

5LO↓, 1,   AP-1↓, 1,   CDH1↑, 1,   DLC1↑, 2,   ITGA5↓, 1,   MMP2↓, 1,   MMP7↓, 1,   MMP9↓, 1,   N-cadherin↓, 1,   Slug↓, 1,   Smad1↑, 1,   Snail↓, 1,   TET1↑, 3,   Twist↓, 1,   Vim↓, 1,   Zeb1↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 2,   VEGF↓, 1,   VEGFR2↓, 1,  

Barriers & Transport ⓘ

SVCT-2∅, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   CXCL1↓, 1,   CXCR4↓, 1,   IL1↓, 1,   IL10↓, 1,   IL12↓, 1,   IL2↑, 1,   IL6↓, 1,   JAK2↓, 1,   NF-kB↓, 1,   NF-kB↑, 1,   p65↓, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 3,   eff↑, 5,   TET2↓, 1,   TET2↑, 14,  

Clinical Biomarkers ⓘ

EZH2↓, 1,   hTERT/TERT↓, 1,   IL6↓, 1,   Myc↓, 1,  

Functional Outcomes ⓘ

OS↑, 1,   QoL↑, 1,  
Total Targets: 126

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   ROS↓, 1,  

Drug Metabolism & Resistance ⓘ

TET2↑, 1,  
Total Targets: 3

Scientific Paper Hit Count for: TET2, tet oncogene family member 2
12 Vitamin C (Ascorbic Acid)
2 Thymoquinone
1 alpha Linolenic acid
1 Luteolin
1 immunotherapy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:303  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page